Research & Development

At the Novartis Institutes for BioMedical Research (NIBR), the goal is to discover new medicines regularly based on an understanding of molecular mechanisms of disease. NIBR scientists are exploring the intersection of the chemical and biological universes, their focus being medicine combined with bioinformatics, genetics, and imaging tools as well as new chemical and screening technologies. The result: an integrative/reductionist combination that renders the drug discovery process at Novartis a true scientific frontier.

Since 2000 Novartis has had the greatest number of new molecular entities approved by the FDA for clinical use in the United States. With our ongoing focus on diseases with unmet medical needs, NIBR scientists ensure that Novartis maintains its robust pipeline and successful track record in innovative drug discovery.

NIBR is headed by Professor Mark Fishman and headquartered in Cambridge, Massachusetts, USA, with a major research facility in Basel, Switzerland. Other key research sites are located in Horsham, UK; Vienna, Austria; Tsukuba, Japan; East Hanover, New Jersey, USA.

For more information, please visit NIBR
http://www.nibr.com.